AZD4017 / AstraZeneca - LARVOL DELTA

TICSI: Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (clinicaltrials.gov) - P2; N=32; Completed; Sponsor: University of Oxford; Recruiting ➔ Completed

Trial completion • Endocrine Disorders

TICSI: Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (clinicaltrials.gov) - P2; N=32; Recruiting; Sponsor: University of Oxford; Trial completion date: Jan 2019 ➔ Aug 2020; Trial primary completion date: Dec 2018 ➔ Aug 2020

Trial completion date • Trial primary completion date

Glucocorticoids and Skin Healing in Diabetes (GC-SHealD) (clinicaltrials.gov) - P2; N=28; Completed; Sponsor: University of Leeds; Recruiting ➔ Completed

Clinical • Trial completion